CancerWorld article on "Generic cancer drugs that we can trust", covering also the situation in CML with Imatinib going off-patent

2015-03-31 13 29 08-Home - Cancer World - Shaping the future of cancer careGenerics markets are gearing up for the expiry of patents on some of the first targeted cancer drugs. It's good news for greater access, but patients want reassurance that switching to generics won't put them at risk. A new CancerWorld article sheds more light on this issue which is increasingly relevant in CML in so many countries, given Imatinib will be off-patent everywhere latest by 2016. The CML Advocates Network​ has pioneered transparency on Imatinib generics (see and this is covered in this CancerWorld article, quoting CML Advocates Network members in Lithuania and Serbia... See the full article here


Please donate!

Please donate!


Tweet Feed

British report finds room for improvement in standardizing BCR-ABL1 testing for chronic myeloid #leukemia #CML

Retweeted Thursday, 27 April 2017

Want to participate at @EHA_Hematology Congress next June? Apply until 29th April for an #EHA22 fellowship here……

Thursday, 27 April 2017

Looking forward to meet you at the 15th #CML Horizons Conference,Frankfurt,26-28 May. Follow us with #CMLHZ17 +Info……

Wednesday, 26 April 2017